{"id":"8ad06313-8541-56fd-a7cf-2960888d8bbb","stable_key":"db0fc92e-b5ef-5667-a4c5-3ef257edbc9b:glutathione-glynac-large-total-null","predicate":"has_no_significant_effect","statement":"The primary total-GSH endpoint was not significantly increased; high-dose versus placebo p=0.278.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"b72c9421-cba2-5f1f-a268-08e2431c6104","mechanism_event_label":"The main trial result must remain visible alongside favorable subsets.","subject":{"id":"96979ad1-a3a1-5a1b-8f8a-6555a2e20447","slug":"glynac-2022-two-week","display_name":"Glycine plus N-acetylcysteine in the 114-participant two-week trial","entity_type_key":"chemical_species"},"object":{"id":"ed90a7f2-eb1a-50b5-937c-dbf01fafb643","slug":"gsh-total-114-trial","display_name":"Total blood glutathione in the 114-participant GlyNAC trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b72c9421-cba2-5f1f-a268-08e2431c6104","stable_key":"db0fc92e-b5ef-5667-a4c5-3ef257edbc9b:glutathione-glynac-large-total-null-event","event_type":"observed_intervention","label":"The main trial result must remain visible alongside favorable subsets.","description":"The primary total-GSH endpoint was not significantly increased; high-dose versus placebo p=0.278.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"2b507258-430c-51fe-9fd2-e510c2c197a9","slug":"glycine","display_name":"Glycine","entity_type_key":"small_molecule"},"role":"supplemented_precursor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b5fa7a22-e5a7-58d9-9e39-91a611aa431e","slug":"n-acetylcysteine","display_name":"N-Acetyl-L-cysteine","entity_type_key":"small_molecule"},"role":"cysteine_precursor","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"96979ad1-a3a1-5a1b-8f8a-6555a2e20447","slug":"glynac-2022-two-week","display_name":"Glycine plus N-acetylcysteine in the 114-participant two-week trial","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"ed90a7f2-eb1a-50b5-937c-dbf01fafb643","slug":"gsh-total-114-trial","display_name":"Total blood glutathione in the 114-participant GlyNAC trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glutathione-research/35821844.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"843ee2e21e49023605a628216fb9c3c4c69ca1d8f3bb19d10da85d038d6612f3\", \"start_char\": 0, \"end_char\": 2083, \"text_sha256\": \"843ee2e21e49023605a628216fb9c3c4c69ca1d8f3bb19d10da85d038d6612f3\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized controlled dose-ranging trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"2.4, 4.8 or 7.2 g/day GlyNAC, 1:1 ratio, for two weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Primary outcomes were null; the favorable low-GSH/high-MDA subgroup was post hoc and hypothesis-generating.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Glutathione research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"glutathione","display_name":"GSH","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The main trial result must remain visible alongside favorable subsets.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[glutathione-p35821844] A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. (2022). https://pubmed.ncbi.nlm.nih.gov/35821844/ DOI: 10.3389/fragi.2022.852569","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"114 healthy older volunteers; 20 young reference participants","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7908a289-253e-5a68-bf40-24d263cbfe42","evidence_kind":"source_excerpt","locator":"Lines 1269-1280","start_line":1269,"end_line":1280,"excerpt":"### glutathione-glynac-large-total-null\nThe primary total-GSH endpoint was not significantly increased; high-dose versus placebo p=0.278.\nCondition category: normal\nnutrient_topic: Glutathione research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The main trial result must remain visible alongside favorable subsets.\norganism: Human\ntissue_or_cell_type: 114 healthy older volunteers; 20 young reference participants\nexperimental_model: Randomized controlled dose-ranging trial\nlimitations: Primary outcomes were null; the favorable low-GSH/high-MDA subgroup was post hoc and hypothesis-generating.\nexposure: 2.4, 4.8 or 7.2 g/day GlyNAC, 1:1 ratio, for two weeks\nevidence_span: {\"source_cache\": \"artifacts/glutathione-research/35821844.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"843ee2e21e49023605a628216fb9c3c4c69ca1d8f3bb19d10da85d038d6612f3\", \"start_char\": 0, \"end_char\": 2083, \"text_sha256\": \"843ee2e21e49023605a628216fb9c3c4c69ca1d8f3bb19d10da85d038d6612f3\"}\n[glutathione-p35821844] A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. (2022). https://pubmed.ncbi.nlm.nih.gov/35821844/ DOI: 10.3389/fragi.2022.852569","model_system":"Randomized controlled dose-ranging trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [glutathione-p35821844] A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. (2022). https://pubmed.ncbi.nlm.nih.gov/35821844/ DOI: 10.3389/fragi.2022.852569","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9b7417fd-059d-5683-b452-71d1e3cf82d0","stable_key":"import-db0fc92e-b5ef-5667-a4c5-3ef257edbc9b","title":"Glutathione: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"2a5740c4a7e770aafe883fea47909b18bf5e174f211749935130a50f9dea2753","revision_id":"a64016dd-4b72-5954-a72d-0e61de854073","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}